You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

Incidence of VOD/SOS

Know the multiple factors that can impact theIncidence of VOD/SOS

Incidence of VOD/SOS based on a meta-analysis1

Incidence of VODIncidence of VOD

Meta-analysis included both allogeneic and autologous stem-cell transplant patients receiving either RIC or MAC regimens

Historically, factors that may impact incidence include1-4

  • Conditioning regimen
  • Type of transplant
  • Underlying disease
  • Diagnostic criteria used

Incidence of VOD/SOS based on the type of transplant and conditioning regimen

Type of transplant

Incidence based on transplant

Conditioning regimen

Incidence based on conditioning regimen
Reduced-intensity conditioning does not eliminate the risk of VOD/SOS, as many other factors can put patients at risk3,8,9
Learn the risk factors for VOD/SOS 
  1. Moderate-to-severe VOD/SOS.

HSCT=hematopoietic stem-cell transplantation; MAC=myeloablative conditioning; RIC=reduced-intensity conditioning; SOS=sinusoidal obstruction syndrome;
VOD=veno-occlusive disease.

References: 1. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-168. 2. Carreras E, Díaz-Beyá M, Rosiñol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011;17(11):1713-1720. 3. Tsirigotis PD, Resnick IB, Avni B, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transplant. 2014;49(11):1389-1392. 4. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40(10):935-944. 5. Roeker LE, Kim HT, Glotzbecker B, et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(1):137-144. 6. Corbacioglu S, Cesaro S, Faraci M, et al. Lancet. 2012;379(9823):1301-1309. 7. Lewis C, Kim HT, Roeker LE, et al. Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):529-539. 8. Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-912. 9. Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781-789.